Biocon, a global biopharmaceutical enterprise today entered into a licencing agreement with Mylan for three bio-generic insulin products. Kiran Mazumdar, CMD, Biocon, in an interview to CNBC-TV18, says that the company will receive licencing fees from Mylan, however, they will not receive any milestone payments.
first published: Feb 14, 2013 10:31 am
A collection of the most-viewed Moneycontrol videos.
This Tenant Moved from a 100sqft Slum to a Premium Residence | The Tenant
Live: Nifty snaps 4-day winning streak but rises 1% this week | Closing Bell
Live: Can Bihar poll outcome trigger Nifty to reclaim 26,000-mark? | Opening Bell
Live: Nifty holds above 25,900 but off nearly 100 pts from day's high | Closing Bell
